A number of firms have modified their ratings and price targets on shares of Beigene (NASDAQ: BGNE) recently:

  • 5/15/2019 – Beigene was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $149.00 price target on the stock. According to Zacks, “BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company’s clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands. “
  • 5/14/2019 – Beigene had its price target raised by analysts at Morgan Stanley from $200.00 to $210.00. They now have an “overweight” rating on the stock.
  • 5/9/2019 – Beigene had its price target raised by analysts at Piper Jaffray Companies to $180.00. They now have an “overweight” rating on the stock.
  • 5/7/2019 – Beigene was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company’s clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands. “
  • 4/18/2019 – Beigene was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 4/5/2019 – Beigene was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.

Shares of BGNE opened at $129.72 on Thursday. The company has a quick ratio of 7.47, a current ratio of 7.52 and a debt-to-equity ratio of 0.14. Beigene Ltd has a one year low of $105.19 and a one year high of $220.10. The stock has a market capitalization of $7.81 billion, a price-to-earnings ratio of -10.68 and a beta of 1.07.

Beigene (NASDAQ:BGNE) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($2.81) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($3.15) by $0.34. Beigene had a negative net margin of 302.58% and a negative return on equity of 44.75%. The business had revenue of $77.83 million during the quarter, compared to analyst estimates of $55.79 million. During the same period last year, the business posted ($2.03) earnings per share. Beigene’s quarterly revenue was up 139.2% compared to the same quarter last year. Sell-side analysts predict that Beigene Ltd will post -13.16 EPS for the current fiscal year.

In other news, insider Xiaobin Wu sold 5,955 shares of Beigene stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $124.52, for a total transaction of $741,516.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CMO Jane Huang sold 300 shares of Beigene stock in a transaction that occurred on Monday, May 20th. The shares were sold at an average price of $130.12, for a total transaction of $39,036.00. Following the transaction, the chief marketing officer now owns 271,621 shares of the company’s stock, valued at $35,343,324.52. The disclosure for this sale can be found here. Insiders sold 116,003 shares of company stock valued at $15,978,023 over the last 90 days. 13.30% of the stock is currently owned by company insiders.

Hedge funds have recently added to or reduced their stakes in the company. Neuburgh Advisers LLC purchased a new position in shares of Beigene during the fourth quarter valued at approximately $27,000. Advisor Group Inc. lifted its holdings in shares of Beigene by 301.4% during the fourth quarter. Advisor Group Inc. now owns 285 shares of the company’s stock valued at $40,000 after purchasing an additional 214 shares during the last quarter. PNC Financial Services Group Inc. purchased a new position in shares of Beigene during the fourth quarter valued at approximately $46,000. Quadrant Capital Group LLC lifted its holdings in shares of Beigene by 131.8% during the first quarter. Quadrant Capital Group LLC now owns 364 shares of the company’s stock valued at $47,000 after purchasing an additional 207 shares during the last quarter. Finally, Ladenburg Thalmann Financial Services Inc. lifted its holdings in shares of Beigene by 116.5% during the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 355 shares of the company’s stock valued at $47,000 after purchasing an additional 191 shares during the last quarter. Hedge funds and other institutional investors own 79.35% of the company’s stock.

BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer in the People's Republic of China, the United States, and internationally. Its commercial products include ABRAXANE, a chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancers; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia.

Further Reading: How to invest in a bear market

Receive News & Ratings for Beigene Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene Ltd and related companies with MarketBeat.com's FREE daily email newsletter.